Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Financial Incentives and Healthcare Provision: Evidence from an Experimental Aedes aegypti Control Programme in Brazil

Danilo Freire, Umberto Mignozzetti
doi: https://doi.org/10.1101/2021.03.10.21252321
Danilo Freire
†Independent Researcher, , .
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: danilofreire@gmail.com danilofreire@gmail.com
Umberto Mignozzetti
‡Visiting Assistant Professor, Quantitative Theory and Methods Department, Emory University, 532 North Kilgo Circle, 4th Floor, Atlanta, GA 30322, USA, , .
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: umberto.mignozzetti@emory.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Mosquito control is the most effective means of reducing Aedes aegypti infections worldwide. In many developing countries, however, vector management programmes fail to reach their goals due to low worker productivity. Research suggests that financial incentives may increase the productivity of health personnel, yet there is little evidence about the impact of monetary rewards on A. aegypti-reduction strategies. We evaluated whether individual and collective financial incentives improve the performance of healthcare workers fighting A. aegypti, as well as their effect on city-level numbers of dengue hospitalisations.

Methodology/Principal findings We hired and trained subjects to visit households, find A. aegypti breeding sites, and eliminate mosquito larvae in the city of Rio Verde, Brazil. We randomly assigned workers into three groups. The control group received a flat compensation for their tasks, while workers in the two treatment groups received individual and collective monetary bonuses, respectively. Financial rewards increased the number of cleaned breeding sites in both treatment groups (individual and team bonuses), and the collective treatment also improved larvae extermination. The intervention lowered dengue hospitalisations in 10.3%, but the result was not consistent across all model specifications.

Conclusions/Significance A. aegypti control programmes may benefit from alternative compensation schemes, especially when provided to teams. For this strategy to succeed, financial incentives have to be distributed widely as their aggregate effect is limited. More research is needed to assess whether higher worker productivity decreases dengue hospitalisations.

Author Summary Diseases transmitted by the Aedes aegypti mosquito, such as chikungunya, dengue, yellow fever, and Zika, continue to affect thousands of people per year. As there are no safe vaccines for most of these infections, insecticide spraying and breeding site elimination are the best means to fight the mosquito. In several developing countries, which host the majority of A. aegypti infections, anti-mosquito campaigns are carried out inconsistently, thus it is crucial to find ways to improve the productivity of healthcare workers in charge of these tasks. We designed a randomised field experiment that provided individual and collective financial incentives to healthcare agents in a Brazilian city, and we tested the effect of monetary rewards on their productivity and on city-level dengue hospitalisations. We find that financial bonuses improved the number of cleaned breeding sites in both treatment groups (individual and team incentives) and that the collective treatment also improved larvae extermination. The impact of our treatment on city-level hospitalisations was not consistent across all specifications. In sum, financial incentives may be used to boost field productivity in anti-A. aegypti programmes, but further research is required to evaluate how healthcare worker productivity impacts dengue outcomes.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

EGAP pre-registry tool (#20180504AA)

Funding Statement

We thank the FGV Applied Research Centre for funding this research

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

We received IRB from the New York University and Fundacao Getulio Vargas. - NYU IRB number: IRB-FY2017-17 - FGV IRB number: IRB-01/2017

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • * We thank Taylor Boas, Saad Gulzar, Cathy Hafer, Daniel Hidalgo, Dimitri Landa, Rebecca Morton, Adam Przeworski, Catarina Roman, Renard Sexton, David Skarbek, Denis Stukal, and participants at EGAP, MPSA, NYU PE Seminar, and SPSA for their valuable comments. We also thank the FGV Applied Research Centre for funding this research. Each named author has equally contributed to conducting the underlying research and drafting this manuscript. To the best of our knowledge, the authors have no conflict of interest, financial or otherwise. Replication materials are available at http://github.com/danilofreire/incentives-healthcare.

Data Availability

Replication materials are available at http://github.com/danilofreire/incentives-healthcare.

http://github.com/danilofreire/incentives-healthcare

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 19, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Financial Incentives and Healthcare Provision: Evidence from an Experimental Aedes aegypti Control Programme in Brazil
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Financial Incentives and Healthcare Provision: Evidence from an Experimental Aedes aegypti Control Programme in Brazil
Danilo Freire, Umberto Mignozzetti
medRxiv 2021.03.10.21252321; doi: https://doi.org/10.1101/2021.03.10.21252321
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Financial Incentives and Healthcare Provision: Evidence from an Experimental Aedes aegypti Control Programme in Brazil
Danilo Freire, Umberto Mignozzetti
medRxiv 2021.03.10.21252321; doi: https://doi.org/10.1101/2021.03.10.21252321

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Economics
Subject Areas
All Articles
  • Addiction Medicine (76)
  • Allergy and Immunology (194)
  • Anesthesia (54)
  • Cardiovascular Medicine (488)
  • Dentistry and Oral Medicine (89)
  • Dermatology (56)
  • Emergency Medicine (168)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (211)
  • Epidemiology (5661)
  • Forensic Medicine (3)
  • Gastroenterology (215)
  • Genetic and Genomic Medicine (856)
  • Geriatric Medicine (88)
  • Health Economics (229)
  • Health Informatics (759)
  • Health Policy (388)
  • Health Systems and Quality Improvement (250)
  • Hematology (105)
  • HIV/AIDS (181)
  • Infectious Diseases (except HIV/AIDS) (6455)
  • Intensive Care and Critical Care Medicine (388)
  • Medical Education (116)
  • Medical Ethics (28)
  • Nephrology (90)
  • Neurology (845)
  • Nursing (44)
  • Nutrition (141)
  • Obstetrics and Gynecology (161)
  • Occupational and Environmental Health (258)
  • Oncology (514)
  • Ophthalmology (162)
  • Orthopedics (44)
  • Otolaryngology (105)
  • Pain Medicine (47)
  • Palliative Medicine (21)
  • Pathology (149)
  • Pediatrics (248)
  • Pharmacology and Therapeutics (146)
  • Primary Care Research (113)
  • Psychiatry and Clinical Psychology (959)
  • Public and Global Health (2222)
  • Radiology and Imaging (375)
  • Rehabilitation Medicine and Physical Therapy (174)
  • Respiratory Medicine (311)
  • Rheumatology (109)
  • Sexual and Reproductive Health (80)
  • Sports Medicine (82)
  • Surgery (118)
  • Toxicology (25)
  • Transplantation (34)
  • Urology (42)